February 20, 2026

Molecular cause of radiation damage identified

Molecular cause of radiation damage identified

A severe side effect of radiation therapy can be debilitating fibrotic skin damage. Scientists at the German Cancer Research Center (DKFZ) have now identified a key factor in the development of this radiation damage. Modulating this factor could potentially prevent this severe adverse effect.

Radiation therapy is one of the most important “pillars” of cancer treatment. More than half of all cancer patients are treated with radiation during the course of their illness. However, radiation can also damage healthy tissue – especially the skin. These reactions range from acute inflammation and pain to chronic fibrosis, which can significantly impair quality of life and treatment success. Fibrosis is a pathological proliferation of connective tissue in which specialized tissue is replaced by scar-like connective tissue. Despite its clinical significance, the molecular causes of radiation damage are not yet fully understood.

Researchers from the DKFZ and the Medical Center of Ludwig Maximilian University of Munich (LMU) have joined forces to search for strategies to prevent skin damage during radiation therapy or even to treat existing damage. The teams focused on an important cellular signaling pathway that controls the growth of connective tissue cells. During these analyses, the protein Dickkopf-3, which modulates this signaling pathway, emerged as a key factor in radiation-induced skin reactions.

Radiation-induced skin reactions are based on complex biological processes involving cells of the epidermis, connective tissue, and immune cells. The new study shows in human skin* and mice that radiation increases the expression of Dickkopf-3 in keratinocytes, the horn-forming cells of the epidermis. This leads to cellular signals that promote the excess production of reactive oxygen speciesaccelerate cell growth, and activate the connective tissue cells responsible for the formation of scar tissue and fibrosis.

In addition, Dickkopf-3 influences the skin’s immune response: It causes macrophages to transform into a fibrosis-promoting state that promotes inflammation and scarring.

Less fibrosis through blocking Dickkopf-3

A key finding of the study is that genetic blockade of Dickkopf-3 in mouse skin cells significantly reduced radiation-induced skin fibrosis. Importantly, the radiation sensitivity of the cells was not altered by switching off Dickkopf-3.

“Our results all indicate that Dickkopf-3 is a key factor in the development of radiation damage – and thus also a potential therapeutic target that could be used to modulate harmful radiation reactions,” summarizes Peter Huber, one of the heads of study

Co-study leader Roger Sandhoff also emphasizes: “Dickkopf-3 is not only relevant in radiation damage, but also in other chronic fibrotic diseases. The results could therefore have significance far beyond radiotherapy.”

The researchers see the discovery of Dickkopf-3 as a central regulator of the radiation response as the basis for further preclinical and clinical studies. The goal is to develop drugs or therapeutic strategies that modulate Dickkopf-3-mediated signals – to protect the skin and other healthy tissues during cancer treatment.

* Skin biopsies and 3D skin model in culture dish

Li Li, Ramon Lopez Perez, Khuram Shehzad, Richard Jennemann, Claudia Schmidt, Thomas Walle, Alexandra Tietz-Dahlfuß, Elisabeth Grimm, Joscha A. Kraske, Peter Häring, Uladzimir Barayeu, Tobias P. Dick, Luxi Ye, Stephan A. Braun, Michael Hertl, Thomas Worzfeld, Thorsten Wiech, Huihui Ji, Jing Su, Jonathan M. Schneeweiss, Muzi Liu, Katharina Kommoss, Matthias Heikenwälder, Bingwen Zou, Sabrina Mücklich, Kerstin Steinbrink, Verena K. Raker, Wenjun Wu, Elfriede Noessner, Hermann-Josef Gröne, Peter J. Nelson, Roger Sandhoff and Peter E. Huber: Wnt-associated DKK3 in keratinocytes mediates radiation-induced hyperplasia, dermatitis and skin fibrosis.
Signal Transduction and Targeted Therapy, 2026, https://doi.org/10.1038/s41392-025-02541-z

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp